OBJECTIVETo investigate clinical efficacy and safety of CMOD regimen as the first treatment for the aged new-diagnosed patients with peripheral T-cell lymphoma.

METHODSSeventy-six patients diagnosed as peripheral T cell lymphoma according to chemotherapy were divided into the 2 group: A and B groups. The patients in A group received CMOD regimen (38 cases) and the patients in B group received CHOP regiment (38 cases). The clinical efficacy, PFS (progression-free survival), OS and the adverse reactions in the 2 groups were compared.

RESULTSThe total effeciency rate was not statistically different between CMOD(64.52%) and CHOP groups (58.06%) (P>0.05). The adverse reactions in 2 groups were as follows: myelosuppression, mucositis, gastrointestinal reactions, fever, liver dysfunction, neurotoxicity, and alopecia etc. The incidence of alopecia and the grade III and IV of neutropenia in the CMOD group (34.21%, 13.16%) were statistically significantly lower than those in the CHOP group (84.21%, 34.21%) (P<0.05). The progression-free survival and 1-year overall survival of observation group (10.98±2.23 months, 14.43±2.48 months) were significantly higher than those in the CHOP group(8.31±2.62 months, 10.93±2.07 months) (P<0.05).

CONCLUSIONThe clinical efficacy of CMOD regimen has been confirmed to be equivalent with CHOP regimen for the aged new-diagnosed patients with peripheral T-cell lymphoma. This regimen can prolong the progression-free survival and overall survival to some extent and reduce the incidence of hair loss and neutropenia, which may be applied to the clinical practice.